Published in Br J Cancer on October 14, 2014
Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines (2017) 0.79
Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges. Semin Oncol (2015) 0.77
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med (2015) 0.76
FRED 2: an immunoinformatics framework for Python. Bioinformatics (2016) 0.75
Transient Treg depletion enhances therapeutic anti-cancer vaccination. Immun Inflamm Dis (2016) 0.75
Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology (2016) 0.75
ImmunoNodes - graphical development of complex immunoinformatics workflows. BMC Bioinformatics (2017) 0.75
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol (2009) 235.12
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res (2000) 117.00
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Exploring the genomes of cancer cells: progress and promise. Science (2011) 6.16
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics (2011) 5.62
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Selection of successive tumour lines for metastasis. Nat New Biol (1973) 5.03
NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res (2008) 4.53
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 2.22
Cancer genome sequencing: a review. Hum Mol Genet (2009) 2.15
B16 as a mouse model for human melanoma. Curr Protoc Immunol (2001) 1.80
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol (2005) 1.75
Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res (2005) 1.65
Dissection of T-cell antigen specificity in human melanoma. Cancer Res (2012) 1.52
Galaxy LIMS for next-generation sequencing. Bioinformatics (2013) 1.45
DNA copy number, including telomeres and mitochondria, assayed using next-generation sequencing. BMC Genomics (2010) 1.41
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res (2010) 1.38
HLA typing from RNA-Seq sequence reads. Genome Med (2012) 1.34
Targeted cancer therapeutics. Cancer Res (2009) 1.30
Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor. PLoS One (2009) 1.29
Confidence-based somatic mutation evaluation and prioritization. PLoS Comput Biol (2012) 1.25
Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol (2011) 1.15
p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A (1996) 1.11
Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett (2007) 1.07
Developing mRNA-vaccine technologies. RNA Biol (2012) 1.04
Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther (2011) 1.01
Mutant ras epitopes as targets for cancer vaccines. Semin Oncol (1996) 0.96
The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol (2013) 0.94
HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines (2013) 0.94
A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med (2010) 0.92
FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res (2011) 0.87
Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. Cancer Immunol Immunother (2007) 0.86
Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics. RNA Biol (2011) 0.84
Antitumor vaccination with synthetic mRNA: strategies for in vitro and in vivo preclinical studies. Methods Mol Biol (2013) 0.79
Melanoma combination therapies ward off tumor resistance. Nat Biotechnol (2013) 0.79